Bronchiectasis Management

Definition and Pathophysiology

Bronchiectasis is a chronic respiratory disease characterized by permanent bronchial dilatation, chronic cough, sputum production, and recurrent bronchial infections, driven by a vicious cycle of chronic infection, neutrophilic inflammation, impaired mucociliary clearance, and progressive structural lung damage 1, 2
Chronic bacterial infection with Haemophilus influenzae, Pseudomonas aeruginosa, Moraxella catarrhalis, Staphylococcus aureus, and Enterobacteriaceae is a key component of the disease 1, 3
Neutrophilic inflammation linked to persistent bacterial colonization causes elastin degradation and rapid lung function decline 2, 3
Impaired mucociliary clearance from structural damage, airway dehydration, and excessive mucus viscosity contributes to the disease cycle 3
Progressive structural damage perpetuates the disease cycle 1, 2

Quality of life impairment in bronchiectasis is equivalent to severe COPD and idiopathic pulmonary fibrosis 1, 3, 4
Exacerbations drive mortality, lung function decline, and healthcare costs in patients with bronchiectasis 2, 3, 4
50% of European patients with bronchiectasis experience ≥2 exacerbations annually, with one-third requiring hospitalization 1, 4
P. aeruginosa infection confers a 3-fold increased mortality risk, 7-fold increased hospitalization risk, and one additional exacerbation per year in patients with bronchiectasis 1, 3

High-resolution CT (HRCT) is the gold standard for confirming permanent bronchial dilatation in patients with suspected bronchiectasis 5

The primary objectives of bronchiectasis management are to prevent exacerbations, reduce symptoms, improve quality of life, and prevent disease progression (lung function decline and mortality) 1, 2, 4

Airway clearance techniques, such as active cycle of breathing, postural drainage, and manual or mechanical devices, are strongly recommended for patients with chronic productive cough or difficulty expectorating 5, 7
Pulmonary rehabilitation is strongly recommended for patients with impaired exercise capacity, with benefits including improved exercise capacity, reduced cough symptoms, and enhanced quality of life 5, 7

Long-term antibiotics, such as inhaled colistin or gentamicin, are recommended for patients with chronic Pseudomonas aeruginosa infection 1, 3, 5
Macrolides, such as azithromycin, are recommended for patients without Pseudomonas aeruginosa infection who experience ≥3 exacerbations per year 5

Mortality is higher in patients with frequent and severe exacerbations, Pseudomonas aeruginosa infection, and comorbidities such as COPD 1, 3

Underutilization of airway clearance techniques and pulmonary rehabilitation despite strong evidence 5, 7
Failure to identify and treat P. aeruginosa infection aggressively given its dramatic impact on outcomes 1, 3
Inadequate etiological workup missing treatable causes like immunodeficiency or ABPA 5, 6